1,985.00
-4.00
(-0.20%)
May 17 - Close
TYO data delayed by 20 mins - Disclaimer
Currency in JPY
| Range | 1,965.00 - 1,992.00 |
| 52 week | 1,168.00 - 2,014.00 |
| Open | 1,983.00 |
| Vol / Avg. | 1.74M/148.00 |
| Mkt cap | 1.40B |
| P/E | 21.01 |
| Div/yield | 30.00/3.02 |
| EPS | 94.50 |
| Shares | 703.95M |
| Beta | - |
| Inst. own | - |
Events
Jul 29, 2013
Q1 2014 Daiichi Sankyo Co Ltd Earnings Release
Jun 21, 2013
Daiichi Sankyo Co Ltd Annual Shareholder Meeting (Japanese)
May 14, 2013
Full Year 2013 Daiichi Sankyo Co Ltd Earnings Presentation (Japanese)
May 13, 2013
Full Year 2013 Daiichi Sankyo Co Ltd Earnings Release
Apr 25, 2013
Daiichi Sankyo Co Ltd at Biotechnology Industry Organization (BIO) International Convention
Mar 22, 2013
Daiichi Sankyo Co Ltd 3rd Medium-Term Management Plan Fiscal Year 2013-2017 Presentation and Webcast (Japanese) -
Mar 22, 2013
Daiichi Sankyo Co Ltd 5-Year Business Plan FY 2013-2017 Presentation Webcast -
|
|
Key stats and ratios
| Q1 (Mar '13) | 2013 | |
| Net profit margin | 5.06% | 6.83% |
| Operating margin | 1.94% | 9.22% |
| EBITD margin | - | 15.34% |
| Return on average assets | 3.22% | 4.31% |
| Return on average equity | 7.05% | 7.86% |
| Employees | 31,929 | - |
| Carbon Disclosure Rating | - | 52/100 |
Address
3-5-1, Nihonbashi, Hon-cho
CHUO-KU, TKY 103-8426
Japan
+81-3-62251111 (Phone)
CHUO-KU, TKY 103-8426
Japan
+81-3-62251111 (Phone)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company has two business segments. The Daiichi Sankyo Group segment is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing, in Japan, the United States, Europe, China and Brazil markets. The Ranbaxy Group segment is engaged in the research, development, manufacture and sale of pharmaceuticals in overseas markets through Ranbaxy group companies. As of March 31, 2012, it has 107 subsidiaries and three associated companies.
Officers and directors
| Takashi Shoda | Chairman of the Board, Representative Director | |
| Joji Nakayama | President, Chief Executive Officer, Representative Director | |
| Tomoo Yokoi | Executive Officer, Director of Finance and Accounting in Main Administration Unit | |
| Tsutomu Une | Chairman of Subsidiary, Director | |
| Takeshi Ogita | Senior Managing Executive Officer, Chief Director of General Affairs and Human Resources, Chief Director of Vaccine Business in Japan Company, Director | |
| Kazunori Hirokawa M. D., Ph.D. | Senior Managing Executive Officer, Chief Director of Strategy, Director | |
| Yuki Sato | Senior Managing Executive Officer, Chief Director of Supply Chain, Director | |
| Glenn Gormley | Senior Managing Executive Officer, Chief Director of Research & Development | |
| Manabu Sakai | Senior Managing Executive Officer, Chief Director of Administration, Director | |
| Yoshikazu Takano | Senior Managing Executive Officer, Chief Director of Legal Affairs & CSR, Chief Director of Business Promotion in Japan Company |